تداخلات إيماتينيب

…Patients Eplerenone is contraindicated in all patients with: • serum potassium > 5.5 mEq/L at initiation, • creatinine clearance ≤ 30 mL/min, or • concomitant administration of strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir) [see Drug Interactions (7.1) , Clinical Pharmacology (12.3)… (نشرة إبليرينون، موانع الاستعمال)

For patients receiving ELIQUIS at a dose of 2.5 mg twice daily, avoid coadministration with combined P-gp and strong CYP3A4 inhibitors [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3) ] . (نشرة أبيكسابان، التداخلات الدوائية)

WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (نشرة إرغوتامين وكافيين، تحذير مؤطر)

Avoid co-administering erlotinib with strong CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice) or a combined CYP3A4 and CYP1A2 inhibitor (e.g., ciprofloxacin). (نشرة إرلوتينيب، التداخلات الدوائية)

Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A (see CONTRAINDICATIONS ). (نشرة إستازولام، التحذيرات)

Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (نشرة أفانافيل، التداخلات الدوائية)

• CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (نشرة أكالابروتينيب، التداخلات الدوائية)

• taking strong cytochrome P450 3A (CYP3A) inhibitors (e.g., ketoconazole, itraconazole), except ritonavir [see Dosage and Administration (2.5) , Warnings and Precautions (5.5) , Drug Interactions (7.1) ] . (نشرة ألبرازولام، موانع الاستعمال)

Grapefruit juice may also increase plasma concentrations of imatinib; avoid grapefruit juice [see Clinical Pharmacology (12.3)] . (نشرة إيماتينيب، التداخلات الدوائية)

…(Childs-Pugh categories B and C), since alfuzosin blood levels are increased in these patients [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3) ]. with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . in… (نشرة ألفوزوسين، موانع الاستعمال)

Concomitant use of almotriptan tablets and potent CYP3A4 inhibitors should be avoided in patients with renal or hepatic impairment [see Clinical Pharmacology ( 12.3 )] . (نشرة ألموتريبتان، التداخلات الدوائية)

• Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ]. (نشرة إليتريبتان، موانع الاستعمال)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (نشرة أمفيتامين، التحذيرات والاحتياطات)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (نشرة أمفيتامين وديكستروأمفيتامين، التداخلات الدوائية)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (نشرة أوباداسيتينيب، التداخلات الدوائية)

UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (نشرة أوبروجيبانت، موانع الاستعمال)

Cytochrome P450 3A4 Interaction The concomitant use of Oxycodone Hydrochloride Oral Solution with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (نشرة أوكسيكودون، تحذير مؤطر)

Cytochrome P450 3A4 Interaction The concomitant use of oxycodone hydrochloride tablets with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (نشرة أوكسيكودون وباراسيتامول، تحذير مؤطر)

Co-administration with eliglustat is contraindicated in poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. (نشرة إيتراكونازول، تحذير مؤطر)

• Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (نشرة إيرينوتيكان، التداخلات الدوائية)

VYTORIN is contraindicated in the following conditions: Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone) [see Drug Interactions (7.1) ] . (نشرة إيزيتيميب وسيمفاستاتين، موانع الاستعمال)

…bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (نشرة إيفابرادين، موانع الاستعمال)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة باراسيتامول وكودايين، تحذير مؤطر)

Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (نشرة بازوبانيب، التداخلات الدوائية)

• Avoid simultaneous use of propafenone with both a cytochrome P450 2D6 (CYP2D6) inhibitor and a 3A4 inhibitor (CYP3A4). (نشرة بروبافينون، التحذيرات والاحتياطات)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (نشرة بروموكريبتين، التداخلات الدوائية)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. (نشرة بروميثازين وكودايين، تحذير مؤطر)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (نشرة بوبرينورفين، التداخلات الدوائية)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وباراسيتامول وكافيين وكودايين، تحذير مؤطر)

Co-administration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with TRACLEER is not recommended. (نشرة بوسنتان، التداخلات الدوائية)

• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (نشرة بوسوتينيب، التداخلات الدوائية)

Cytochrome P450 3A4 Interaction The concomitant use of DEMEROL Injection with all cytochrome P450 3A4 inhibitors may result in an increase in meperidine plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (نشرة بيثيدين، تحذير مؤطر)

Concomitant administration of BIXLENVO with combined P-gp, UGT1A1, and strong CYP3A inhibitors is not recommended. (نشرة بيكتيغرافير وإمتريسيتابين وتينوفوفير ألافيناميد، التداخلات الدوائية)

Concomitant use of pimozide with paroxetine and other strong CYP 2D6 inhibitors is contraindicated (See PRECAUTIONS – DRUG INTERACTIONS ). (نشرة بيموزيد، موانع الاستعمال)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

CYP3A inhibitors: Avoid concomitant strong CYP3A inhibitors ( 7.1 ) (نشرة ترابيكتيدين، التداخلات الدوائية)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (نشرة ترازودون، التحذيرات والاحتياطات)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (نشرة ترامادول، تحذير مؤطر)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (نشرة ترامادول وباراسيتامول، تحذير مؤطر)

Strong CYP 3A Inhibitors Triazolam is contraindicated in patients receiving strong inhibitors of CYP 3A such as ketoconazole, itraconazole, nefazodone, ritonavir, indinavir, nelfinavir, saquinavir, and lopinavir [see Contraindications (4) , Drug Interactions (7.1) ] . (نشرة تريازولام، التحذيرات والاحتياطات)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (نشرة تريتينوين، التداخلات الدوائية)

Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided [see Warnings and Precautions (5.1) ] . (نشرة توريميفين، تحذير مؤطر)

…dominant polycystic kidney disease (ADPKD) outside of FDA-approved REMS [see Warnings and Precautions (5.2) ] Unable to sense or respond to thirst Hypovolemic hyponatremia Taking strong CYP3A inhibitors [see Warnings and Precautions (5.5) ] Anuria Hypersensitivity (e.g., anaphylactic shock, rash generalized) to tolvaptan or any components of the product [see Adverse… (نشرة تولفابتان، موانع الاستعمال)

Avoid co-administration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with TEPADINA due to the potential effects on efficacy and toxicity [see Clinical Pharmacology ( 12.3 ) ] . (نشرة ثيوتيبا، التداخلات الدوائية)

Strong CYP3A4 inhibitors: Avoid concomitant use. (نشرة داريدوريكسانت، التداخلات الدوائية)

Avoid concomitant use of strong CYP3A4 inhibitors. (نشرة داساتينيب، التداخلات الدوائية)

Drug-Drug Interactions Strong Inhibitors of Cytochrome P450 (CYP) 3A4 Tamsulosin-containing products, including JALYN, should not be coadministered with strong CYP3A4 inhibitors (e.g., ketoconazole) as this can significantly increase tamsulosin exposure [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ]. (نشرة دوتاستيريد وتامسولوسين، التحذيرات والاحتياطات)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (نشرة دوسيتاكسيل، التداخلات الدوائية)

Avoid concomitant use of Doxorubicin Hydrochloride Injection with inhibitors of CYP3A4, CYP2D6, or P-gp. (نشرة دوكسوروبيسين، التداخلات الدوائية)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (نشرة ديكساميثازون، التداخلات الدوائية)

If serotonin syndrome occurs, discontinue dextroamphetamine sulfate and the CYP2D6 inhibitor [see Warnings , Overdosage ]. (نشرة ديكستروأمفيتامين، التداخلات الدوائية)

QT Prolongation: Monitor ECG if concomitant use of drugs that prolong QT interval cannot be avoided or if concomitant CYP3A4 inhibitors used. (نشرة ديكستروميثورفان وكينيدين، التحذيرات والاحتياطات)

WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH POTENT CYP3A4 INHIBITORS Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. (نشرة ديهيدروإرغوتامين، تحذير مؤطر)

Use with P-gp and Strong CYP3A Inhibitors or Inducers Avoid concomitant use of XARELTO with known combined P-gp and strong CYP3A inhibitors [see Drug Interactions (7.2) ] . (نشرة ريفاروكسابان، التحذيرات والاحتياطات)

• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (نشرة ريميجيبانت، التداخلات الدوائية)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (نشرة سالميتيرول، التداخلات الدوائية)

Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated [see Warnings and Precautions (5.1) , Drug Interactions (7.1) ] . (نشرة سوزيتريجين، موانع الاستعمال)

Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (نشرة سوفوسبوفير وفيلباتاسفير، التداخلات الدوائية)

The dosage of Solifenacin succinate tablets greater than 5 mg once daily is not recommended when concomitantly used with strong CYP3A4 inhibitors [see Dosage and Administration ( 2.4 )] . (نشرة سوليفيناسين، التداخلات الدوائية)

Interaction with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp Avoid concomitant use of sirolimus with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) [ see Drug Interactions (7.2) ]. (نشرة سيروليموس، التحذيرات والاحتياطات)

Severe renal impairment (CCr < 30 mL/min) Severe hepatic impairment (Child-Pugh score ≥ 10) Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) [see DRUG INTERACTIONS (7.1) ] Patients with a history of hypersensitivity to silodosin or any of the ingredients in silodosin capsules… (نشرة سيلودوسين، موانع الاستعمال)

ZOCOR is contraindicated in the following conditions: Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone) [see Drug Interactions (7.1) ] . (نشرة سيمفاستاتين، موانع الاستعمال)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (نشرة فلوتيكازون، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (نشرة فليبانسيرين، تحذير مؤطر)

• Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of fentanyl. (نشرة فنتانيل، تحذير مؤطر)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (نشرة فيبديغيسترانت، التحذيرات والاحتياطات)

CYP3A4 Inhibitors Doses of Toviaz greater than 4 mg are not recommended in adult patients taking strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, and clarithromycin [see Dosage and Administration (2.5) ]. (نشرة فيسوتيرودين، التداخلات الدوائية)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (نشرة فينكريستين، التداخلات الدوائية)

Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) while taking COMETRIQ or reduce the dosage of COMETRIQ if concomitant use with strong CYP3A4 inhibitors cannot be avoided [see Dosage and Administration ( 2.2 ), Clinical Pharmacology… (نشرة كابوزانتينيب، التداخلات الدوائية)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة كودايين، تحذير مؤطر)

Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [see Drug Interactions (7) ] . (نشرة كولشيسين، موانع الاستعمال)

…should not be used within at least 72 hours of treatment with ketoconazole Antineoplastics irinotecan dasatinib, lapatinib, nilotinib bortezomib, busulphan, docetaxel, erlotinib, imatinib, ixabepilone, paclitaxel, trimetrexate, vinca alkaloids Irinotecan: The potential increase in plasma concentrations of irinotecan when coadministered with ketoconazole tablets… (نشرة كيتوكونازول، التداخلات الدوائية)

Avoid strong CYP3A4 inhibitors. (نشرة لاباتينيب، التداخلات الدوائية)

Strong CYP3A4 Inhibitors: Avoid coadministration of strong CYP3A4 inhibitors with VITRAKVI. (نشرة لاروتريكتينيب، التداخلات الدوائية)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions ( 7.1 )]. (نشرة لوراسيدون، موانع الاستعمال)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (نشرة لورلاتينيب، التداخلات الدوائية)

Concomitant administration with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone and cobicistat-containing products) (see WARNINGS , Myopathy/Rhabdomyolysis ). (نشرة لوفاستاتين، موانع الاستعمال)

Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (نشرة لوميتابيد، موانع الاستعمال)

If concomitant use of VYVANSE with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate VYVANSE with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (نشرة ليسديكسامفيتامين، التحذيرات والاحتياطات)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (نشرة ليمبوريكسانت، التداخلات الدوائية)

SELZENTRY is contraindicated in patients with severe renal impairment or ESRD (creatinine clearance [CrCl] less than 30 mL per minute) who are concomitantly taking potent CYP3A inhibitors or inducers [see Warnings and Precautions ( 5.3 )]. (نشرة مارافيروك، موانع الاستعمال)

Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (نشرة ماسيتنتان، التداخلات الدوائية)

Strong CYP3A Inhibitors and Inducers: Avoid concomitant use. (نشرة ميتابيفات، التداخلات الدوائية)

CYP2D6 Inhibitors Monitor patients closely when the combination use of CYP2D6 inhibitor and metoprolol cannot be avoided. (نشرة ميتوبرولول، التداخلات الدوائية)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The concomitant use of METHADOSE with all cytochrome P450 3A4, 2B6, 2C19, 2C9 or 2D6 inhibitors may result in an increase in methadone plasma concentrations, which could cause potentially fatal respiratory depression. (نشرة ميثادون، تحذير مؤطر)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (نشرة ميثامفيتامين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Patients concomitantly using strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) because these medications can significantly increase exposure to naloxegol which may precipitate opioid withdrawal symptoms such as hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning [see Drug Interactions (7.1) and Clinical Pharmacology… (نشرة نالوكسيغول، موانع الاستعمال)

نبتة سانت جون قد تضعف هذه الأدوية بتسريع تفككها، مما قد يعني رفض العضو المزروع أو الجلطات أو فقدان المفعول. (NCCIH, St. John's Wort)

CYP3A4 inhibitors and inducers : SULAR is substrate of CYP3A4 and coadministration of SULAR with any known inducer or inhibitor of CYP3A4 should be avoided in general. (نشرة نيسولديبين، التداخلات الدوائية)

Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 , 7.2 )] . (نشرة نيلوتينيب، تحذير مؤطر)

Therefore, the concomitant administration of NYMALIZE and strong CYP3A4 inhibitors should generally be avoided [ see Warnings and Precautions (5.3) ]. (نشرة نيموديبين، التداخلات الدوائية)

Cytochrome P450 3A4 Interaction The concomitant use of HYSINGLA ER with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (نشرة هيدروكودون، تحذير مؤطر)

Cytochrome P450 3A4 Interaction The concomitant use of Hydrocodone Bitartrate and Ibuprofen Tablets with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which may cause potentially fatal respiratory depression. (نشرة هيدروكودون وإيبوبروفين، تحذير مؤطر)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (نشرة هيدروكودون وباراسيتامول، تحذير مؤطر)

Cytochrome P450 3A4 Interaction The concomitant use of Hydrocodone Polistirex and Chlorpheniramine Polistirex with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. (نشرة هيدروكودون وكلورفينيرامين، تحذير مؤطر)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and homatropine methylbromide with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. (نشرة هيدروكودون وهوماتروبين، تحذير مؤطر)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Strong CYP2D6 Inhibitors Prevention or Management With concomitant use of atomoxetine oral solution and a strong CYP2D6 inhibitor 1 , increase the titration interval [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3) ] . (نشرة أتوموكسيتين، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

CYP2D6 inhibitors and CYP3A4 Inhibitors : See full prescribing information for ABILIFY MAINTENA dosage modifications when used concomitantly with CYP2D6 inhibitors and/or CYP3A4 inhibitors for greater than 14 days ( 7.1 ) (نشرة أريبيبرازول، التداخلات الدوائية)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects. (نشرة إستراديول، التداخلات الدوائية)

…exposure at steady state. [See Clinical Pharmacology (12.3).] Substances Increasing the Systemic Exposure of COCs (enzyme inhibitors): Concomitant administration of moderate or strong CYP3A4 inhibitors like azole antifungals (for example, ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (for example, clarithromycin, erythromycin), diltiazem,… (نشرة إستراديول ودينوجيست، التداخلات الدوائية)

Inducers and/or inhibitors of CYP3A4 may affect estrogen drug metabolism and decrease or increase the estrogen plasma concentration. (نشرة إستراديول ونوريثيستيرون، التداخلات الدوائية)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (نشرة إستروجينات مقترنة وبازيدوكسيفين، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (نشرة إسزوبيكلون، التحذيرات والاحتياطات)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

CYP3A4/5 Inhibitors Co-administration of ketoconazole, a strong inhibitor of CYP3A4/5, increased the plasma exposure of axitinib in healthy volunteers. (نشرة أكسيتينيب، التداخلات الدوائية)

…(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (نشرة إلترومبوباغ، التداخلات الدوائية)

Coadministration of GENVOYA with other drugs that inhibit CYP3A may decrease the clearance and increase the plasma concentration of cobicistat. (نشرة إلفيتيغرافير وكوبيسيستات وإمتريسيتابين وتينوفوفير، التداخلات الدوائية)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (نشرة ألوسيترون، التداخلات الدوائية)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (نشرة إليكساكافتور وتيزاكافتور وإيفاكافتور، التحذيرات والاحتياطات)

Drugs Inducing or Inhibiting CYP3A Enzymes Rilpivirine is primarily metabolized by cytochrome P450 (CYP) 3A, and drugs that induce or inhibit CYP3A may thus affect the clearance of RPV [see Contraindications (4) , Warnings and Precautions (5.7) , and Clinical Pharmacology (12.3) ] . (نشرة إمتريسيتابين وريلبيفيرين وتينوفوفير، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (نشرة أوكسيبوتينين، التداخلات الدوائية)

Inhibitors of CYP2D6 Fluoxetine: Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. (نشرة أولانزابين، التداخلات الدوائية)

The Effect of Other Drugs on Olanzapine — Fluoxetine, an inhibitor of CYP2D6, decreases olanzapine clearance a small amount [see Clinical Pharmacology ( 12.3 )]. (نشرة أولانزابين وفلوكسيتين، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Increase in Plasma Concentrations of ella Associated with Co-Administered Drugs CYP3A4 inhibitors such as itraconazole or ketoconazole increase plasma concentrations of ella [see Pharmacokinetics (12.3) ] . (نشرة أوليبريستال، التداخلات الدوائية)

Risk of Use in Patients with Decreased Cytochrome P450 2D6 Function or Concomitant Use or Discontinuation with Cytochrome P450 3A4 Inhibitors and Inducers Risk of Increased Oliceridine Plasma Concentrations Increased plasma concentrations of oliceridine, which may result in prolonged opioid adverse reactions and exacerbated respiratory depression, may occur when… (نشرة أوليسيريدين، التحذيرات والاحتياطات)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of omeprazole [see Clinical Pharmacology ( 12.3 )] . (نشرة أوميبرازول، التداخلات الدوائية)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of omeprazole [see Clinical Pharmacology ( 12.3 )] . (نشرة أوميبرازول وبيكربونات الصوديوم، التداخلات الدوائية)

Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the coadministration of Umeclidinium and Vilanterol ELLIPTA with ketoconazole and other known strong cytochrome P450 3A4 (CYP3A4) inhibitors (including, but not limited to, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone,… (نشرة أوميكليدينيوم وفيلانتيرول، التحذيرات والاحتياطات)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

Concomitant administration of strong or moderate CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma estrogen and/or progestin concentrations. (نشرة إيتونوجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

Potential for other drugs to affect ivacaftor CYP3A inhibitors: Reduce KALYDECO dosage in patients aged 6 months and older when co-administered with strong CYP3A inhibitors (e.g., ketoconazole) or moderate CYP3A inhibitors (e.g., fluconazole). (نشرة إيفاكافتور، التداخلات الدوائية)

• CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (نشرة إيفوسفاميد، التداخلات الدوائية)

The dose of FANAPT should be reduced in patients co-administered a strong CYP2D6 or CYP3A4 inhibitor. (نشرة إيلوبيريدون، التداخلات الدوائية)

Exposure of Paricalcitol Injection will increase upon coadministration with strong CYP3A inhibitors [see Clinical Pharmacology (12.3) ] . (نشرة باريكالسيتول، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Impact of Other Drugs on Propranolol CYP2D6, CYP1A2 and CYP2C19 Inhibitors: CYP2D6 inhibitors (e.g. bupropion, fluoxetine, paroxetine, quinidine), CYP1A2 inhibitors (e.g., ciprofloxacin, enoxamine, fluvoxamine) and CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) increase exposure to propranolol when co-administered with INNOPRAN XL. (نشرة بروبرانولول، التداخلات الدوائية)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (نشرة بريكسبيبرازول، التداخلات الدوائية)

Effects of Other Drugs on the Pharmacokinetics of Primaquine Strong CYP2D6 Inhibitors Published clinical and non-clinical reports indicate reduced CYP2D6 activity may decrease the formation of active metabolites of primaquine, which may reduce antimalarial efficacy of Primaquine phosphate Tablets (see CLINICAL PHARMACOLOGY, Pharmacogenomics ). (نشرة بريماكين، التداخلات الدوائية)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (نشرة بريمونيدين وتيمولول، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

Inhibitors of CYP3A4 Clinical Impact: The concomitant use of buprenorphine and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of buprenorphine and naloxone sublingual tablet is achieved. (نشرة بوبرينورفين ونالوكسون، التداخلات الدوائية)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (نشرة بورتيزوميب، التداخلات الدوائية)

Other inhibitors and inducers of CYP3A4: Substances that inhibit CYP3A4, such as ketoconazole or ritonavir, may inhibit buspirone metabolism and increase plasma concentrations of buspirone while substances that induce CYP3A4, such as dexamethasone or certain anticonvulsants (phenytoin, phenobarbital, carbamazepine), may increase the rate of buspirone metabolism. (نشرة بوسبيرون، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (نشرة بيتوليسانت، التداخلات الدوائية)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Strong CYP3A4 Inhibitors: Reduce NUPLAZID dose to 10 mg once daily. (نشرة بيمافانسيرين، التداخلات الدوائية)

…Physicians should be aware that CIALIS for once daily use provides continuous plasma tadalafil levels and should consider this when evaluating the potential for interactions with medications (e.g., nitrates, alpha-blockers, anti-hypertensives and potent inhibitors of CYP3A4) and with substantial consumption of alcohol [see Drug Interactions ( 7.1 , 7.2 , 7.3 )] . (نشرة تادالافيل، التحذيرات والاحتياطات)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (نشرة تاكروليموس، التحذيرات والاحتياطات)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

Table 7: Clinically Significant Interactions Affecting XELJANZ/XELJANZ XR When Concomitantly Used with Other Drugs Strong CYP3A4 Inhibitors (e.g., ketoconazole) Clinical Impact Increased exposure to tofacitinib Intervention Dosage modification of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration (2) , Clinical Pharmacology, Figure 3 (12.3) ] Moderate… (نشرة توفاسيتينيب، التداخلات الدوائية)

Drug Interactions CYP3A4 Inhibitors Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions ). (نشرة تولتيرودين، التداخلات الدوائية)

• Do not exceed 50 mg/day and the maximum single dose should not exceed 25 mg if administered in conjunction with a strong CYP2D6 inhibitor (e.g., fluoxetine, paroxetine). (نشرة تيترابينازين، التحذيرات والاحتياطات)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (نشرة تيمسيروليموس، التحذيرات والاحتياطات)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine) and timolol. (نشرة تيمولول، التداخلات الدوائية)

Simultaneous administration of drugs that inhibit the activity of liver microsomal enzymes, i.e., CYP3A4 inhibitors such as cimetidine and ketoconazole, may prolong the half-life and decrease the plasma clearance of tinidazole, increasing the plasma concentrations of tinidazole. (نشرة تينيدازول، التداخلات الدوائية)

Co-administration of darunavir and ritonavir and other drugs that inhibit CYP3A, or P-gp may decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of darunavir and ritonavir (see Table 10 ). (نشرة دارونافير، التداخلات الدوائية)

Co-administration of PREZCOBIX or PREZCOBIX PED and other drugs that inhibit CYP3A may result in increased plasma concentrations of darunavir and cobicistat (see Table 2 ). (نشرة دارونافير وكوبيسيستات، التداخلات الدوائية)

CYP3A4 Inhibitors The systemic exposure of darifenacin from darifenacin extended-release tablets is increased in the presence of CYP3A4 inhibitors. (نشرة داريفيناسين، التداخلات الدوائية)

Consider monitoring serum potassium concentration in high-risk patients who take a strong CYP3A4 inhibitor long-term and concomitantly. (نشرة دروسبيرينون وإيثينيل إستراديول، التحذيرات والاحتياطات)

Monitor for increased dronabinol-related adverse reactions when dronabinol oral solution is co-administered with inhibitors of CYP2C9 (e.g., amiodarone, fluconazole) and inhibitors of CYP3A4 enzymes (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin, grapefruit juice). (نشرة درونابينول، التداخلات الدوائية)

Effects of Other Drugs on Dronedarone Ketoconazole and Other Potent CYP3A Inhibitors Concomitant use of ketoconazole as well as other potent CYP3A inhibitors such as itraconazole, voriconazole, ritonavir, clarithromycin, and nefazodone is contraindicated because exposure to dronedarone is significantly increased [see Contraindications (4) , Clinical Pharmacology… (نشرة درونيدارون، التداخلات الدوائية)

Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. (نشرة دورافيرين، التداخلات الدوائية)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (نشرة دورزولاميد وتيمولول، التداخلات الدوائية)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (نشرة دوفيتيليد، التداخلات الدوائية)

Strong cytochrome P450 (CYP) 3A inhibitors may increase exposure to doxazosin and increased risk of hypotension. (نشرة دوكسازوسين، التداخلات الدوائية)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations. (نشرة ديسوجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of dexlansoprazole is expected when used concomitantly with strong inhibitors [see Clinical Pharmacology (12.3) ] . (نشرة ديكسلانسوبرازول، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (نشرة ديوتيترابينازين، التداخلات الدوائية)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (نشرة راميلتيون، التداخلات الدوائية)

Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in vivo plasma clearance of ropivacaine. (نشرة روبيفاكايين، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (نشرة روفلوميلاست، التداخلات الدوائية)

Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (نشرة روكسوليتينيب، التداخلات الدوائية)

• Monitor for toxicities related to increased romidepsin exposure when co-administering romidepsin with strong CYP3A4 inhibitors ( 7.2 ). (نشرة روميديبسين، التداخلات الدوائية)

CYP2C8 and CYP3A4 Inhibitors Intervention: Repaglinide tablets dose reductions and increased frequency of glucose monitoring may be required when co‑administered. (نشرة ريباغلينيد، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (نشرة ريسبيريدون، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

Coadministration of EDURANT or EDURANT PED and drugs that inhibit CYP3A may result in increased plasma concentrations of rilpivirine. (نشرة ريلبيفيرين، التداخلات الدوائية)

As zafirlukast is known to be an inhibitor of CYP3A4 in vitro , it is reasonable to employ appropriate clinical monitoring when these drugs are coadministered with zafirlukast. (نشرة زافيرلوكاست، الاحتياطات)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (نشرة زاليبلون، التداخلات الدوائية)

CYP3A4 Inhibitors Ketoconazole Ketoconazole, a potent CYP3A4 inhibitor, increased the exposure to and pharmacodynamic effects of zolpidem. (نشرة زولبيديم، التداخلات الدوائية)

Ketoconazole Ketoconazole, a potent inhibitor of CYP3A4, at a dose of 400 mg QD for 5 days, increased the AUC and C max of ziprasidone by about 35 to 40%. (نشرة زيبراسيدون، التداخلات الدوائية)

Strong Inhibitors of CYP3A4/5 Enzymes Ketoconazole significantly increased saxagliptin exposure. (نشرة ساكساغليبتين، التداخلات الدوائية)

Strong Inhibitors of CYP3A4/5 Enzymes Ketoconazole significantly increased saxagliptin exposure. (نشرة ساكساغليبتين وميتفورمين، التداخلات الدوائية)

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil). (نشرة سوفوريكسانت، التداخلات الدوائية)

Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (نشرة سونيتينيب، التحذيرات والاحتياطات)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

…methylprednisolone Allopurinol nicardipine itraconazole clarithromycin Amiodarone verapamil ketoconazole erythromycin Bromocriptine voriconazole quinupristin/ dalfopristin colchicine danazol imatinib metoclopramide nefazodone oral contraceptives HIV Protease Inhibitors The HIV protease inhibitors (e.g., indinavir, nelfinavir, ritonavir, and saquinavir) are known to inhibit… (نشرة سيكلوسبورين، التداخلات الدوائية)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (نشرة سيلدينافيل، التداخلات الدوائية)

Inhibitors of CYP3A4 or CYP2C19 Inhibitors of CYP3A4 Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to cilostazol. (نشرة سيلوستازول، التداخلات الدوائية)

Co-administration with a strong CYP3A4 inhibitor may increase serum levels of cinacalcet. (نشرة سيناكالسيت، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

…Interactions: Effect of other Drugs on INTUNIV Concomitant Drug Name or Drug Class Clinical Rationale and Magnitude of Drug Interaction Clinical Recommendation Strong and moderate CYP3A4 inhibitors, e.g., ketoconazole, fluconazole Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in an increase… (نشرة غوانفاسين، التداخلات الدوائية)

• CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (نشرة غيفيتينيب، التداخلات الدوائية)

Potential for Drug Interactions with Strong or Moderate CYP3A4 Inhibitors Concomitant administration with strong CYP3A4 inhibitors (such as ritonavir, indinavir, cobicistat, ketoconazole) or moderate CYP3A4 inhibitors (such as erythromycin) increases plasma concentrations of vardenafil. (نشرة فاردينافيل، التحذيرات والاحتياطات)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (نشرة فالبينازين، التحذيرات والاحتياطات)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (نشرة فلوفوكسامين، التحذيرات والاحتياطات)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

• Strong inhibitors of CYP2D6: Reduce TRINTELLIX dose by half when coadministered ( 2.5 , 7.1 ). (نشرة فورتيوكسيتين، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

CYP3A4 Inhibitors: The VIIBRYD dose should not exceed 20 mg once daily when co-administered with strong CYP3A4 inhibitors ( 2.4 , 7 ). (نشرة فيلازودون، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

CYP2D6 Substrates Clinical Impact Viloxazine is a weak inhibitor of CYP2D6, and increases the exposure of CYP2D6 substrates when coadministered [see Clinical Pharmacology (12.3) ] . (نشرة فيلوكسازين، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

Inhibitors of CYP3A4: May cause earlier onset and/or increased severity of adverse reactions ( 7.1 ) (نشرة فينوريلبين، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (نشرة كارفيديلول، التداخلات الدوائية)

Clinically Significant Drug Interactions with VRAYLAR Strong or Moderate CYP3A4 Inhibitors Clinical Impact: Concomitant use of VRAYLAR with a strong or moderate CYP3A4 inhibitor increases the exposures of cariprazine and its major active metabolite, didesmethylcariprazine (DDCAR), compared to use of VRAYLAR alone [see Clinical Pharmacology ( 12.3 ) ]. (نشرة كاريبرازين، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

CYP2D6 and CYP3A4 Inhibitors Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology ( 12.3 )] . (نشرة كلوزابين، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Inhibitors of CYP3A4 and CYP3A5 Inhibitors of CYP3A4 and/or CYP3A5 may increase plasma concentrations of clindamycin [ see Clinical Pharmacology (12.3) ]. (نشرة كليندامايسين، التداخلات الدوائية)

• Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one‑sixth when coadministered with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) ( 2.5 , 7.1 , 12.3 ) (نشرة كويتيابين، التداخلات الدوائية)

Although a causal relationship between a specific drug and the arrhythmia was not established in this case, erythromycin is a CYP3A4 inhibitor and has been shown to increase quinine plasma levels when used concomitantly. (نشرة كينين، التحذيرات والاحتياطات)

Strong CYP3A4 or CYP2C9 Inhibitors Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to VIMPAT. (نشرة لاكوساميد، التداخلات الدوائية)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of lansoprazole is expected when used concomitantly with strong inhibitors [see Clinical Pharmacology (12.3) ] . (نشرة لانسوبرازول، التداخلات الدوائية)

Drug Interactions Effects of Other Drugs on Loperamide Concomitant use of loperamide hydrochloride capsules with inhibitors of CYP3A4 (e.g., itraconazole) or CYP2C8 (e.g., gemfibrozil) or inhibitors of P-glycoprotein (e.g., quinidine, ritonavir) can increase exposure to loperamide. (نشرة لوبيراميد، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (نشرة لوفيكسيدين، التداخلات الدوائية)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

CYP3A inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice The effect of grapefruit juice on CYP3A4 enzymes (e.g., strong vs. moderate inhibition) depends on its brand, concentration, and preparation. , or ketoconazole may increase systemic exposure of the estrogen and/or progestin component of CHCs. (نشرة ليفونورجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

CYP2D6 inhibitors: Increased metoprolol concentration. (نشرة ميتوبرولول وهيدروكلوروثيازيد، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

• Strong CYP2D6 inhibitors (e.g., quinidine, bupropion, fluoxetine, and paroxetine) : See Full Prescribing Information for recommended dosage reductions. (نشرة ميتوكلوبراميد، التداخلات الدوائية)

Gleevec may delay the clearance of methotrexate when methotrexate is used at high doses (> 500 mg/m 2 ). (نشرة إيماتينيب، التداخلات الدوائية)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Examples phenytoin, carbamazepine, rifampin Strong CYP3A Inhibitors Clinical Impact The concomitant use of strong CYP3A inhibitors with REMERON/REMERONSolTab may increase the plasma concentration of mirtazapine [see Clinical Pharmacology (12.3) ] . (نشرة ميرتازابين، التداخلات الدوائية)

Ketoconazole (Potent Inhibitor of CYP3A4) Coadministration of a single 500 mg oral dose of mefloquine with 400 mg of ketoconazole once daily for 10 days in 8 healthy volunteers resulted in an increase in the mean C max and AUC of mefloquine by 64% and 79%, respectively, and an increase in the mean elimination half-life of mefloquine from 322 hours to 448 hours. (نشرة ميفلوكين، التداخلات الدوائية)

…mifepristone is contraindicated. [See Contraindications (4.3)] 5.6 Use of Strong CYP3A Inhibitors Mifepristone should be used with caution in patients taking ketoconazole and other strong inhibitors of CYP3A, such as itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir, fosamprenavir, clarithromycin, conivaptan, lopinavir/ritonavir, posaconazole,… (نشرة ميفيبريستون، التحذيرات والاحتياطات)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact : Increased exposure of esomeprazole [see Clinical Pharmacology (12.3) ]. (نشرة نابروكسين وإيزوميبرازول، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (نشرة نالديميدين، التداخلات الدوائية)

Concomitant administration of CYP3A4 inhibitors such as itraconazole, fluconazole, grapefruit juice or ketoconazole may increase plasma hormone concentrations. (نشرة نورجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations. (نشرة نورجيستيمات وإيثينيل إستراديول، التداخلات الدوائية)

Substances increasing the systemic concentrations of HCs: Co-administration of certain HCs and strong or moderate CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase the systemic concentrations of progestins, including norethindrone. (نشرة نوريثيستيرون، التداخلات الدوائية)

CYP3A4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone levels. (نشرة نوريثيستيرون وإيثينيل إستراديول، التداخلات الدوائية)

CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations. (نشرة نوريلجيسترومين وإيثينيل إستراديول، التداخلات الدوائية)

Use with CYP2D6 Inhibitors Nebivolol exposure increases with inhibition of CYP2D6 [see Drug Interactions ( 7 ) ] . (نشرة نيبيفولول، التحذيرات والاحتياطات)

…Astemizole, Cisapride, and Pimozide Interactions Terfenadine, astemizole, cisapride, and pimozide are all metabolized by the cytochrome P450 3A4 (CYP3A4) isozyme, and it has been demonstrated that ketoconazole, erythromycin, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. (نشرة نيفازودون، التحذيرات)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (نشرة نينتيدانيب، التداخلات الدوائية)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

The effect of CYP3A4 inhibition and of decreased CYP2D6 enzyme may be additive. (نشرة هالوبيريدول، التداخلات الدوائية)

In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (نشرة إيماتينيب، التحذيرات والاحتياطات)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (نشرة إيماتينيب، التحذيرات والاحتياطات)

…cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, fosamprenavir, imatinib, indinavir, isoniazid, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, nilotinib, oral contraceptives, posaconazole, ranitidine, ranolazine, ritonavir,… (نشرة وارفارين، التداخلات الدوائية)

Potential for REYATAZ to Affect Other Drugs Atazanavir is an inhibitor of CYP3A and UGT1A1. (نشرة أتازانافير، التداخلات الدوائية)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

TAF is a weak inhibitor of CYP3A in vitro . (نشرة إمتريسيتابين وتينوفوفير، التداخلات الدوائية)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (نشرة إيريبولين، التداخلات الدوائية)

Patients who require anticoagulation should receive low-molecular weight or standard heparin and not warfarin. (نشرة إيماتينيب، التداخلات الدوائية)

Hypothyroidism has been reported in thyroidectomy patients undergoing levothyroxine replacement. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Effects of Noxafil and Noxafil PowderMix on Other Drugs Posaconazole is a strong CYP3A4 inhibitor. (نشرة بوساكونازول، التداخلات الدوائية)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (نشرة تاموكسيفين، التداخلات الدوائية)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Hypothyroidism has been reported in thyroidectomy patients undergoing levothyroxine replacement. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

Although potent inhibitors of cytochrome P450 3A4 (e.g., ketoconazole) have not been studied clinically, in vitro studies have shown that erythromycin and oleandomycin inhibit the metabolism of disopyramide. (نشرة ديسوبيراميد، التداخلات الدوائية)

Effects of Other Drugs on Ranolazine Strong CYP3A Inhibitors Concomitant use of ASPRUZYO Sprinkle with strong CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir is contraindicated [see Contraindications (4), Clinical Pharmacology (12.3)]. (نشرة رانولازين، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

However, no formal drug-drug interaction studies between zileuton and CYP3A4 inhibitors, such as ketaconazole, have been conducted. (نشرة زيلوتون، التداخلات الدوائية)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Drugs Metabolized by CYP2D6 Clinical Impact: Sertraline hydrochloride capsules are a CYP2D6 inhibitor [see Clinical Pharmacology ( 12.3 )] . (نشرة سيرترالين، التداخلات الدوائية)

Drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline. (نشرة سيفيميلين، التداخلات الدوائية)

CYP2D6 substrates Clinical Impact: In vitro studies indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. (نشرة سيليكوكسيب، التداخلات الدوائية)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

An in vitro study using human liver microsomes suggests that famciclovir is not an inhibitor of CYP3A4 enzymes. (نشرة فامسيكلوفير، التداخلات الدوائية)

Additionally, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than fluoxetine or norfluoxetine as an inhibitor of the metabolism of several substrates for this enzyme, including astemizole, cisapride, and midazolam. (نشرة فلوكسيتين، التداخلات الدوائية)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Because ritonavir is a CYP2D6 inhibitor, clinically significant interactions with drugs metabolized by CYP2D6 are possible when coadministered with fosamprenavir calcium plus ritonavir. (نشرة فوسامبرينافير، التداخلات الدوائية)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. (نشرة كلاريثرومايسين، التداخلات الدوائية)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Hypothyroidism has been reported in thyroidectomy patients undergoing levothyroxine replacement. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Hypothyroidism has been reported in thyroidectomy patients undergoing levothyroxine replacement. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Effect of SUNLENCA on Other Drugs Lenacapavir is a moderate inhibitor of CYP3A. (نشرة ليناكابافير، التداخلات الدوائية)

Hypothyroidism has been reported in thyroidectomy patients undergoing levothyroxine replacement. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Hypothyroidism has been reported in thyroidectomy patients undergoing levothyroxine replacement. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (نشرة ميمانتين ودونيبيزيل، التداخلات الدوائية)

Potential for PAXLOVID to Affect Other Drugs PAXLOVID (nirmatrelvir co-packaged with ritonavir) is a strong inhibitor of CYP3A, and an inhibitor of CYP2D6, P-gp and OATP1B1. (نشرة نيرماتريلفير وريتونافير، التداخلات الدوائية)

Patients who require anticoagulation should receive low-molecular weight or standard heparin and not warfarin. (نشرة إيماتينيب، التداخلات الدوائية)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (نشرة إيماتينيب، التحذيرات والاحتياطات)

Other HIV Protease Inhibitors (CYP3A4 Inhibition) In Vivo Studies Showed No Significant Effects of Indinavir on Voriconazole Exposure In Vitro Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism (Increased Plasma Exposure) No dosage adjustment in the voriconazole dosage needed for concomitant administration with indinavir. (نشرة فوريكونازول، التداخلات الدوائية)